The second edition of the joint WHO, WIPO and WTO
publication “Promoting Access to Medical Technologies
and Innovation: Intersections between public health,
intellectual property and trade” (the Trilateral Study),*
published in 2020, included a special insert mappi...ng the
challenges posed by the COVID-19 pandemic in relation
to the integrated health, trade and IP policy framework set
out in the study. The Trilateral Study and the special insert
were designed to serve as background reference for policy-
makers in the widest sense – lawmakers, government
officials, delegates to international organizations, non-
governmental organizations (NGOs) and researchers
who seek a comprehensive presentation of the full range
of issues, including institutions and legal concepts with
which they may be unfamiliar. It is also designed to serve
as a factual resource for the three organizations’ technical
cooperation activities.
This update revises the information contained in that
insert in the light of more recent developments as of
30 August 2021. Further updates will be made to reflect
subsequent developments.
more
Medical devices are used for the prevention, diagnosis and treatment of illness and diseases and for rehabilitation. WHO developed guidance on medical device donation in 2011, which has been now reviewed, with new evidence, new references on considerations for medical device solicitation and provisi...on, risks associated with inappropriate donations, the responsibilities of donors and recipient, and the steps they should follow before, during and after a donation. It includes three sections: description of major problems that may be faced during the donation process, listing of best practices for donors and recipients and addressing situations requiring special attention. It also has three annexes for further reading: the criteria for the acceptability of a donation, literature review on donations of medical devices between 2010 and 2023 and a flyer. This document is intended to improve the quality of medical devices donations, including medical equipment, single-use medical devices and in-vitro diagnostics, to provide maximum benefit to all stakeholders. The considerations can be used to develop institutional or national policies and regulations for medical devices donations. This document is intended for use by any organization, expert or practitioner involved in the donation, procurement, management of medical devices, including health workers, biomedical engineers, health managers, policymakers, donors, nongovernmental organizations and academic institutions.
more
Building on previous guidelines, the People In Aid Code seeks to offer agencies an effective framework for human resources management, helping them assess and raise their performance.
Standard Treatment Guidelines
This position paper on polio vaccines replaces the 2016 WHO position paper, and summarizes recent developments in the field.
Le cadre de surveillance basé sur les événements est destiné à être utilisé par les autorités et les
agences responsables de la surveillance et de l'intervention. Ce cadre sert de cadre pour guider les
parties prenantes intéressées par la mise en œuvre de la surveillance basée sur le...s événements (SBÈ)
en utilisant une approche multisectorielle axée sur l'approche « Une seule santé ». À cette fin, le
document est organisé en chapitres et annexes interconnectés qui peuvent être modifiés et adaptés,
selon les besoins, par les utilisateurs.
Il s'agit d'une version révisée du « Cadre pour la surveillance basée sur les événements » original qui
a été publié en 2018. Ce cadre ne remplace aucun autre matériel SBÈ disponible, mais s'appuie plutôt
sur des documents pertinents ou connexes existants et sert de guide pratique pour la mise en œuvre
de l'SBÈ en Afrique. Ce cadre est conforme à la troisième édition de l'évaluation externe conjointe de
l'OMS pour les indicateurs suivants : systèmes d'alerte précoce renforcés capables de détecter les
événements importants pour la santé publique et la sécurité sanitaire (indicateur D2.1) ; amélioration
de la communication et de la collaboration entre les secteurs et entre les niveaux d'autorité nationaux,
intermédiaires et locaux d'intervention en matière de santé publique en matière de surveillance des
événements importants pour la santé publique (indicateur D2.2) ; et amélioration de la capacité
d'analyse des données aux niveaux national et intermédiaire ( Indicateur D2.3). Au fur et à mesure
que les pays commenceront à mettre en œuvre et à démontrer la fonctionnalité SBÈ, ils garantiront
une augmentation des scores EEC et des progrès vers le respect des exigences décrites dans l'RSI
(Règlement sanitaire international).
En outre, dans les États membres de l'Union africaine qui ont adopté la Surveillance et réponse
intégrées aux maladies (SRIM), ce document complète et peut améliorer la mise en œuvre de l'SRIM,
en particulier pour la 3e édition (2019) qui inclut des composants liés à l'SBÈ.
more
JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, Vol. 28, No. 2, March/April 2017, 186-198
http://dx.doi.org/10.1016/j.jana.2015.09.003
Orientations provisoires, 28 janvier 2021
Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de... sécurité biologique relatifs à la réalisation des tests diagnostiques rapides antigéniques, manipulation des nouveaux variants du SARS-CoV-2 au laboratoire, mise à jour de la décontamination des tests avant leur élimination, équipement de protection individuelle (EPI) pour le prélèvement d’échantillons et, même s’ils ne concernent pas directement la sécurité biologique, dangers chimiques et leur élimination en toute sécurité.
more
Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the
leading cause of premature mortality in low and middle income countries (LMICs).
Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisector...al population-based interventions to reduce CVD risk factors in the entire population.
Methods: We describe key public health considerations in identifying and managing individuals at high risk of CVD in LMICs.
Results: A main objective of any strategy to identify individuals at high CVD risk is to maximize the number of CVD events averted while minimizing the numbers of
individuals needing treatment. Scores estimating the total risk of CVD (e.g. ten-year risk of fatal and non-fatal CVD) are available for LMICs, and are based on the main CVD risk factors (history of CVD, age, sex, tobacco use, blood pressure, blood cholesterol and diabetes status). Opportunistic screening of CVD risk factors enables identification of persons with high CVD risk, but this strategy can be widely applied in low resource settings only if cost effective interventions are used (e.g. the WHO Package of Essential NCD interventions for primary health care in low resource settings package) and if treatment (generally for years) can be sustained, including continued availability ofaffordable medications and funding mechanisms that allow people to purchase medications without impoverishing them (e.g. universal access to health care). Thisalso emphasises the need to re-orient health systems in LMICs towards chronic diseases management.
Conclusion: The large burden of CVD in LMICs and the fact that persons with high
CVD can be identified and managed along cost-effective interventions mean that
health systems need to be structured in a way that encourages patient registration, opportunistic screening of CVD risk factors, efficient procedures for the management of chronic conditions (e.g. task sharing) and provision of affordable treatment for those with high CVD risk. The focus needs to be in primary care because that is where most of the population can access health care and because CVD programmes can be run effectively at this level.
more
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World
Institute of Medicine (US) Committee on Nervous System Disorders in Developing Countries.
Washington (DC): National Academies Press (US); 2001.
This document provides up-to-date guidance on laboratory studies as well as smallscale (semi-field) and large-scale field trials to assess the efficacy and determine field application rates of new molluscicide products for control of schistosomiasis.
The WHO guidelines provide recommended steps for safe phlebotomy and reiterate accepted principles for drawing, collecting blood and transporting blood to laboratories/blood banks.
Mugisha et al. Int J Ment Health Syst (2017) 11:7 DOI 10.1186/s13033-016-0114-2